Treatment of Sepsis-Induced Acquired Protein C Deficiency Reverses Angiotensin-Converting Enzyme-2 Inhibition and Decreases Pulmonary Inflammatory Response

The protein C (PC) pathway plays an important role in vascular and immune function, and acquired deficiency during sepsis is associated with increased mortality in both animal models and in clinical studies. However, the association of acquired PC deficiency with the pathophysiology of lung injury is unclear. We hypothesized that low PC induced by sepsis would associate with increased pulmonary injury and that replacement with activated protein C (APC) would reverse the activation of pathways associated with injury. Using a cecal ligation and puncture (CLP) model of polymicrobial sepsis, we examined the role of acquired PC deficiency on acute lung injury assessed by analyzing changes in pulmonary pathology, chemokine response, inducible nitric-oxide synthase (iNOS), and the angiotensin pathway. Acquired PC deficiency was strongly associated with an increase in lung inflammation and drivers of pulmonary injury, including angiotensin (Ang) II, thymus and activation-regulated chemokine, plasminogen activator inhibitor (PAI)-1, and iNOS. In contrast, the protective factor angiotensin-converting enzyme (ACE)-2 was significantly suppressed in animals with acquired PC deficiency. The endothelial protein C receptor, required for the cytoprotective signaling of APC, was significantly increased post-CLP, suggesting a compensatory up-regulation of the signaling receptor. Treatment of septic animals with APC reduced pulmonary pathology, suppressed the macrophage inflammatory protein family chemokine response, iNOS expression, and PAI-1 activity and up-regulated ACE-2 expression with concomitant reduction in AngII peptide. These data demonstrate a clear link between acquired PC deficiency and pulmonary inflammatory response in the rat sepsis model and provide support for the concept of APC as a replacement therapy in acute lung injury associated with acquired PC deficiency.

[1]  J. Vincent,et al.  Beneficial effects of recombinant human activated protein C in a ewe model of septic shock* , 2007, Critical care medicine.

[2]  Nigel Mackman,et al.  Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein C , 2007, The Journal of experimental medicine.

[3]  R. Paus,et al.  IL-15 constrains mast cell–dependent antibacterial defenses by suppressing chymase activities , 2007, Nature Medicine.

[4]  Shaoheng He,et al.  Induction of monocyte chemoattractant protein-1 release from A549 cells by agonists of protease-activated receptor-1 and -2. , 2007, European journal of cell biology.

[5]  C. Su,et al.  INHIBITION OF INDUCIBLE NITRIC OXIDE SYNTHASE ATTENUATES ACUTE ENDOTOXIN‐INDUCED LUNG INJURY IN RATS , 2007, Clinical and experimental pharmacology & physiology.

[6]  G. Sandusky,et al.  Role of protein C in renal dysfunction after polymicrobial sepsis. , 2007, Journal of the American Society of Nephrology : JASN.

[7]  J. Vincent,et al.  Why do patients who have acute lung injury/acute respiratory distress syndrome die from multiple organ dysfunction syndrome? Implications for management. , 2006, Clinics in chest medicine.

[8]  J. Nick,et al.  Systemic Inhibition of the Angiotensin-Converting Enzyme Limits Lipopolysaccharide-Induced Lung Neutrophil Recruitment through Both Bradykinin and Angiotensin II-Regulated Pathways1 , 2006, The Journal of Immunology.

[9]  J. Simecka,et al.  Cytokine and Chemokine Transcription Profile during Mycoplasma pulmonis Infection in Susceptible and Resistant Strains of Mice: Macrophage Inflammatory Protein 1β (CCL4) and Monocyte Chemoattractant Protein 2 (CCL8) and Accumulation of CCR5+ Th Cells , 2006, Infection and Immunity.

[10]  M. Matthay,et al.  Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[11]  R. Hardaway.  A Brief Overview of Acute Respiratory Distress Syndrome , 2006, World Journal of Surgery.

[12]  G. Bernard,et al.  The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. , 2006, Seminars in respiratory and critical care medicine.

[13]  D. Haines,et al.  Respiratory dysfunction and proinflammatory chemokines in the pneumonia virus of mice (PVM) model of viral bronchiolitis. , 2006, Virology.

[14]  J. Penninger,et al.  Angiotensin-converting enzyme 2 in lung diseases , 2006, Current Opinion in Pharmacology.

[15]  R. Neviere,et al.  Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response , 2006, Respiratory research.

[16]  Arthur S Slutsky,et al.  Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia—A review , 2006, Critical care medicine.

[17]  R. L. Grubbs,et al.  FoxA2 Involvement in Suppression of Protein C, an Outcome Predictor in Experimental Sepsis , 2006, Clinical and Vaccine Immunology.

[18]  C. Ferrario,et al.  Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1–7) in regulation of cardiovascular function , 2005, American journal of physiology. Heart and circulatory physiology.

[19]  D. Mennerich,et al.  Characterization of Toll-like receptors in primary lung epithelial cells: strong impact of the TLR3 ligand poly(I:C) on the regulation of Toll-like receptors, adaptor proteins and inflammatory response , 2005, Journal of inflammation.

[20]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.

[21]  B. Dahlbäck,et al.  The anticoagulant protein C pathway , 2005, FEBS letters.

[22]  T. van der Poll,et al.  Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. , 2005, American journal of respiratory and critical care medicine.

[23]  S. Sone,et al.  Elevation of macrophage-derived chemokine in eosinophilic pneumonia: a role of alveolar macrophages. , 2005, The journal of medical investigation : JMI.

[24]  Jerry A Nick,et al.  Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. , 2004, Blood.

[25]  H. Sarau,et al.  Angiotensin II Induces Neutrophil Accumulation In Vivo Through Generation and Release of CXC Chemokines , 2004, Circulation.

[26]  R. L. Grubbs,et al.  Evaluation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis* , 2004, Critical care medicine.

[27]  D. Nelson,et al.  Severe protein C deficiency predicts early death in severe sepsis , 2004, Critical care medicine.

[28]  R. Veldhuizen,et al.  Negative impact of tissue inhibitor of metalloproteinase-3 null mutation on lung structure and function in response to sepsis. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[29]  C. Ahn,et al.  Inducible nitric oxide synthase inhibitors prolonged the survival of skin xenografts through selective down-regulation of pro-inflammatory cytokine and CC-chemokine expressions. , 2003, Transplant immunology.

[30]  J. Vincent,et al.  Epidemiology and outcome of acute respiratory failure in intensive care unit patients , 2003, Critical care medicine.

[31]  H. Razavi,et al.  Role of inducible nitric oxide synthase in pulmonary microvascular protein leak in murine sepsis. , 2002, American journal of respiratory and critical care medicine.

[32]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[33]  K. Robison,et al.  A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9 , 2000, Circulation research.

[34]  T. Nakajima,et al.  Thrombin receptor mediated signals induce expressions of interleukin 6 and granulocyte colony stimulating factor via NF-κB activation in synovial fibroblasts , 1999, Annals of the rheumatic diseases.

[35]  S. Hussain,et al.  Contribution of macrophages to pulmonary nitric oxide production in septic shock. , 1998, American journal of respiratory and critical care medicine.

[36]  B. Grinnell,et al.  Mutation of Protease Domain Residues Lys37-39 in Human Protein C Inhibits Activation by the Thrombomodulin-Thrombin Complex without Affecting Activation by Free Thrombin* , 1996, The Journal of Biological Chemistry.

[37]  Z. Xia,et al.  Effect of NO donor sodium nitroprusside on lipopolysaccharide induced acute lung injury in rats. , 2007, Injury.

[38]  J. Griffin,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only. The cytoprotective protein C pathway , 2006 .

[39]  L. O'Brien,et al.  Activated protein C and sepsis. , 2006, Frontiers in bioscience : a journal and virtual library.

[40]  E. Abraham,et al.  Effects of Recombinant Human Activated Protein C in Human Models of Endotoxin Administration Intravenous Administration of Endotoxin , 2022 .